BLOODPAC's collaborations with European Union liquid biopsy initiatives
The Journal of Liquid Biopsy · 2025-12 · 10 · 100321
DOI: 10.1016/j.jlb.2025.100321 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Liquid Biopsy, 2025-12. Verfasst von Jennifer Dickey und 24 weiteren Autor:innen. Beteiligte Einrichtung: Labcorp, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Blood Profiling Atlas in Cancer, European Commission.
Abstract (Originalsprache)
The adoption of liquid biopsy into clinical practice has revolutionized the landscape of cancer diagnostics and treatment monitoring. In the U.S., the Blood Profiling Atlas in Cancer (BLOODPAC) has significantly supported the advancement of these technologies through consensus building [1]. In collaboration with the United States (US) Food and Drug Administration (FDA), BLOODPAC has developed minimum technical data elements (MTDEs) and analytical validation protocols to streamline the assay development and regulatory assessment of liquid biopsy-based technologies. Additionally, BLOODPAC has established a pre-competitive data sharing model to support clinical implementation. The European Union faces regulatory and access challenges that hinder widespread adoption of liquid biopsy technologies. Complexities under the In Vitro Diagnostic Regulation (IVDR) and Clinical Trials Regulation (CTR) have introduced variability and delays across member states. While recognizing Europe's strengths in developing robust frameworks and high standards for advancing precision oncology, this paper explores how BLOODPAC's efforts-particularly in standardization, validation, and data sharing-could inform and complement EU initiatives. BLOODPAC's experience in developing fit-for-purpose validation frameworks and fostering regulatory-industry dialogue offers particularly relevant insights for addressing EU-specific challenges. This paper proposes opportunities for collaboration and guidance development that could enhance European access to liquid biopsy-based tests for precision medicine, ultimately improving patient access and outcomes for cancer care and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Labcorp, USA.
- Tempus AI, Inc, USA.
- BLOODPAC, USA.
- Oncology Regulatory Science, Strategy, and Excellence, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Cancer Patients Europe, Belgium.
- Natera, USA.
Förderung
- Blood Profiling Atlas in Cancer
- European Commission
Zitieren
APA
Dickey, J., Katrivanos, E., Leiman, L. C., Abukhdeir, A. M., Cardone, A., Saritas-Yildirim, B., Galamba, C., Jankiewicz, C., Rolfo, C., Bhandari, D., Finnegan, E., Fenizia, F., Celik, H., Mehlhorn, I., Walker, J., Costa, J. L., Williams, K., Sewart, M., Olsen, M., …, & Gonzales, V. (2025). BLOODPAC's collaborations with European Union liquid biopsy initiatives. The Journal of Liquid Biopsy, 10, 100321. https://doi.org/10.1016/j.jlb.2025.100321
Vancouver
Dickey J, Katrivanos E, Leiman LC, Abukhdeir AM, Cardone A, Saritas-Yildirim B, et al. BLOODPAC's collaborations with European Union liquid biopsy initiatives. The Journal of Liquid Biopsy. 2025;10:100321. doi:10.1016/j.jlb.2025.100321
BibTeX
@article{Dickey2025,
author = {Dickey, Jennifer and Katrivanos, Elaine and Leiman, Lauren C and Abukhdeir, Abde M and Cardone, Antonella and Saritas-Yildirim, Banu and Galamba, Carlos and Jankiewicz, Cheyenne and Rolfo, Christian and Bhandari, Deepshikha and Finnegan, Emily and Fenizia, Francesca and Celik, Haydar and Mehlhorn, Ingrid and Walker, Jillian and Costa, Jose Luis and Williams, Kathy and Sewart, Mark and Olsen, Matias and Wierzba, Michael and Sanzone, Pia and Fijneman, Remond J A and Dumanois, Robert and Mbella, Valerie and Gonzales, Veronica},
title = {BLOODPAC's collaborations with European Union liquid biopsy initiatives},
journal = {The Journal of Liquid Biopsy},
year = {2025},
volume = {10},
pages = {100321},
doi = {10.1016/j.jlb.2025.100321}
}
EUVIMED